Geron Corporation Logo

Geron Corporation

0IV3.L

(0.0)
Stock Price

4,67 USD

0% ROA

-63.33% ROE

0x PER

Market Cap.

1.080.697.360,00 USD

10.27% DER

0% Yield

-77691.14% NPM

Geron Corporation Stock Analysis

Geron Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Geron Corporation Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Geron Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Geron Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Geron Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Geron Corporation Revenue
Year Revenue Growth
2012 2.709.000
2013 1.283.000 -111.15%
2014 1.153.000 -11.27%
2015 36.371.000 96.83%
2016 6.162.000 -490.25%
2017 1.065.000 -478.59%
2018 1.066.000 0.09%
2019 460.000 -131.74%
2020 253.000 -81.82%
2021 1.393.000 81.84%
2022 596.000 -133.72%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Geron Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2012 51.368.000
2013 23.155.000 -121.84%
2014 20.707.000 -11.82%
2015 17.831.000 -16.13%
2016 18.047.000 1.2%
2017 11.033.000 -63.57%
2018 13.432.000 17.86%
2019 52.072.000 74.2%
2020 51.488.000 -1.13%
2021 85.727.000 39.94%
2022 95.518.000 10.25%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Geron Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 20.397.000
2013 15.624.000 -30.55%
2014 16.758.000 6.77%
2015 17.793.000 5.82%
2016 18.761.000 5.16%
2017 19.287.000 2.73%
2018 18.707.000 -3.1%
2019 20.893.000 10.46%
2020 25.678.000 18.63%
2021 29.665.000 13.44%
2022 43.628.000 32%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Geron Corporation EBITDA
Year EBITDA Growth
2012 -68.226.000
2013 -37.176.000 -83.52%
2014 -36.265.000 -2.51%
2015 803.000 4616.19%
2016 -30.565.000 102.63%
2017 -29.179.000 -4.75%
2018 -31.014.000 5.92%
2019 -72.441.000 57.19%
2020 -76.755.000 5.62%
2021 -113.784.000 32.54%
2022 -138.262.000 17.7%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Geron Corporation Gross Profit
Year Gross Profit Growth
2012 -22.469.000
2013 -7.851.000 -186.19%
2014 -7.748.000 -1.33%
2015 26.797.000 128.91%
2016 -8.533.000 414.04%
2017 -7.372.000 -15.75%
2018 -11.657.000 36.76%
2019 -50.812.000 77.06%
2020 -49.799.000 -2.03%
2021 -83.136.000 40.1%
2022 -93.668.000 11.24%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Geron Corporation Net Profit
Year Net Profit Growth
2012 -68.881.000
2013 -38.379.000 -79.48%
2014 -35.670.000 -7.59%
2015 46.000 77643.48%
2016 -29.537.000 100.16%
2017 -27.916.000 -5.81%
2018 -27.017.000 -3.33%
2019 -68.548.000 60.59%
2020 -75.617.000 9.35%
2021 -116.112.000 34.88%
2022 -141.901.000 18.17%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Geron Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -1
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Geron Corporation Free Cashflow
Year Free Cashflow Growth
2012 -56.008.000
2013 -36.683.000 -52.68%
2014 9.219.000 497.91%
2015 -24.286.000 137.96%
2016 -18.426.000 -31.8%
2017 -20.556.000 10.36%
2018 -21.025.000 2.23%
2019 -44.242.000 52.48%
2020 -67.053.000 34.02%
2021 -95.763.000 29.98%
2022 -127.810.000 25.07%
2023 -51.031.000 -150.46%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Geron Corporation Operating Cashflow
Year Operating Cashflow Growth
2012 -55.146.000
2013 -36.680.000 -50.34%
2014 9.350.000 492.3%
2015 -24.196.000 138.64%
2016 -18.369.000 -31.72%
2017 -20.556.000 10.64%
2018 -21.009.000 2.16%
2019 -43.829.000 52.07%
2020 -66.652.000 34.24%
2021 -95.556.000 30.25%
2022 -127.379.000 24.98%
2023 -50.839.000 -150.55%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Geron Corporation Capital Expenditure
Year Capital Expenditure Growth
2012 862.000
2013 3.000 -28633.33%
2014 131.000 97.71%
2015 90.000 -45.56%
2016 57.000 -57.89%
2017 0 0%
2018 16.000 100%
2019 413.000 96.13%
2020 401.000 -2.99%
2021 207.000 -93.72%
2022 431.000 51.97%
2023 192.000 -124.48%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Geron Corporation Equity
Year Equity Growth
2012 85.653.000
2013 59.757.000 -43.34%
2014 130.711.999 54.28%
2015 142.126.000 8.03%
2016 122.380.000 -16.13%
2017 103.797.000 -17.9%
2018 177.733.000 41.6%
2019 135.155.000 -31.5%
2020 210.947.000 35.93%
2021 126.416.000 -66.87%
2022 79.998.000 -58.02%
2023 290.614.000 72.47%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Geron Corporation Assets
Year Assets Growth
2012 99.801.000
2013 67.344.000 -48.2%
2014 172.511.000 60.96%
2015 148.760.000 -15.97%
2016 130.249.000 -14.21%
2017 110.313.000 -18.07%
2018 185.284.000 40.46%
2019 165.517.000 -11.94%
2020 270.728.000 38.86%
2021 226.034.000 -19.77%
2022 190.575.000 -18.61%
2023 413.017.000 53.86%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Geron Corporation Liabilities
Year Liabilities Growth
2012 14.148.000
2013 7.587.000 -86.48%
2014 41.799.000 81.85%
2015 6.634.000 -530.07%
2016 7.869.000 15.69%
2017 6.516.000 -20.76%
2018 7.551.000 13.71%
2019 30.362.000 75.13%
2020 59.781.000 49.21%
2021 99.618.000 39.99%
2022 110.577.000 9.91%
2023 122.403.000 9.66%

Geron Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
0x
Price To Sales Ratio
0x
POCF Ratio
0
PFCF Ratio
-6.63
Price to Book Ratio
0
EV to Sales
0
EV Over EBITDA
0
EV to Operating CashFlow
-6.48
EV to FreeCashFlow
-6.45
Earnings Yield
0
FreeCashFlow Yield
-0.15
Market Cap
1,08 Bil.
Enterprise Value
1,05 Bil.
Graham Number
0
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0
Income Quality
0.93
ROE
0
Return On Assets
-0.47
Return On Capital Employed
-0.68
Net Income per EBT
1
EBT Per Ebit
0.95
Ebit per Revenue
-818.33
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
-2.24
Operating Profit Margin
-818.33
Pretax Profit Margin
-776.91
Net Profit Margin
-776.91

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0.01
Capex to Revenue
0
Capex to Depreciation
-0.89
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0.1
Debt to Assets
0.07
Net Debt to EBITDA
0
Current Ratio
3.75
Tangible Asset Value
0,29 Bil.
Net Current Asset Value
0,21 Bil.
Invested Capital
0.1
Working Capital
0,25 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
0
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Geron Corporation Dividends
Year Dividends Growth
2022 0

Geron Corporation Profile

About Geron Corporation

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

CEO
Dr. John A. Scarlett M.D.
Employee
141
Address
919 East Hillsdale Boulevard
Foster City, 94404

Geron Corporation Executives & BODs

Geron Corporation Executives & BODs
# Name Age
1 Dr. Andrew J. Grethlein Ph.D.
Executive Vice President & Chief Operating Officer
70
2 Ms. Shannon Odam
Senior Vice President & Chief People Officer
70
3 Ms. Michelle J. Robertson
Executive Vice President, Chief Financial Officer, Treasurer and Principal Financial & Accounting Officer
70
4 Mr. Anil Kapur
Executive Vice President of Corporate Strategy & Chief Commercial Officer
70
5 Dr. Faye Feller M.D.
Executive Vice President & Chief Medical Officer
70
6 Ms. Melissa A. Kelly Behrs
Executive Vice President of Business Operations & Chief Alliance Officer
70
7 Mr. Scott Samuels
Executive Vice President, Chief Legal Officer & Corporate Secretary
70
8 Mr. Edward E. Koval
Executive Vice President & Chief Business Officer
70
9 Ms. Aron Feingold
Vice President of Investor Relations & Corporate Communications
70
10 Dr. John A. Scarlett M.D.
Chairman of the Board, President & Chief Executive Officer
70

Geron Corporation Competitors